|Neuren Pharmaceuticals Limited|
697 Burke Road
Australia - Map
Phone: 61 3 9092 0480
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products in development include Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion; and NNZ-2591, a synthetic analogue of a naturally occurring neuropeptide that is in preclinical development for the treatment of various neurodegenerative disorders. The company has collaborative relationships with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.
|Dr. Richard Spencer Treagus BScMed, MBChB, MPharmMed, MBA,
|Mr. Lawrence Glass BA (Biology),
Chief Science Officer and Exec. Director
|Mr. Jonathan Charles Pilcher BSc (Hons), ACA,
Chief Financial Officer and Company Sec.
|Dr. Joseph Horrigan ,
VP of Clinical Devel. & Medical Affairs
|Dr. Nancy E. Jones Ph.D.,
Sr. Director of Clinical Devel. and Medical Affairs
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|